Sisters in Health: A Weight Loss Study for African American Women
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL · Dec 11, 2015
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
A disparity exists in the prevalence of overweight and obesity between non-Hispanic white (NHW) and African American (AA) women. More AA women (78.2%) are overweight or obese compared to NHW (61.2%). Obesity increases the risk of developing numerous chronic diseases, including type 2 diabetes (T2DM), hypertension, cardiovascular disease, and some cancers. Among AA women, there is a higher prevalence, and almost double the risk, of developing T2DM compared to NHW. African Americans also have higher rates of complications and mortality from T2DM, and are more at risk for hypertension compared...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 21-65 years old
- • Ability to read, write, and speak English
- • Female gender
- • African American/Black/African/Afro-Caribbean race (self-identified)
- • BMI 25-45 (\> 45 may have greater risks while participating)
- • Meets criteria for low active (defined as \<3 days/week of at most 20 min. of PA/day) assessed by X
- • Willingness to be randomized
- • Willingness to participate for 6 months, including attending face-to-face sessions \& outside of session tasks
- • Access to a computer reliable internet access
- • Willingness to use an app for diet and physical activity monitoring
- • Regularly used email address
- • Not planning to relocate
- • Able to attend group sessions on scheduled day
- Exclusion Criteria:
- • Recently lost weight, 5-10% in last 6 months
- • Currently participating in another weight loss or PA study, or taking weight loss medication, and unwilling to discontinue those activities
- • Pregnant or planning to become pregnant
- • Any physical limitations to engaging in or increasing physical activity/exercise- assessed by PAR-Q (including but not limited to heart attack/myocardial infarction, congestive heart failure)
- • Type 2 diabetes being treated with insulin
- • Major psychological disorder
- • History of diagnosed eating disorder
- • Medications that affect weight (determined by study staff)
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Deborah F. Tate, PhD
Study Chair
University of North Carolina, Chapel Hill
Loneke T. Blackman Carr, MA, RD
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials